IKE Tech's PMTA for First-Ever Standalone Age-Gating System at Point of Use Accepted for FDA Review Just One Month After Submission
The organization's blockchain technology is set to redefine public health safeguards and help end youth vaping for good.
LOS ANGELES, June 4, 2025 /PRNewswire/ -- IKE Tech LLC ('IKE Tech'), a leading innovator at the intersection of Internet of Things (IoT), identity verification, and tokenization technology, has received an Acceptance Review letter from the U.S. Food and Drug Administration (FDA) for its Premarket Tobacco Product Application (PMTA), just one month after submission on April 26. This marks the first time the FDA has proceeded with a PMTA for a standalone, interoperable age-gating component providing real-time age verification at the point of use for electronic nicotine delivery systems (ENDS).
Potentially compatible with all ENDS devices, the IKE system integrates a Bluetooth Low Energy (BLE) System-on-a-Chip with the smartphone-enabled IKE Mobile Application, enabling secure, continuous age and identity verification. In a multi-center Human Factors Validation Study, submitted with the PMTA, 0% of underage users were able to activate a device, showcasing the reliability of IKE Tech's blockchain-based technology in safeguarding public health.
Receipt of the FDA's Acceptance letter confirms that the IKE Tech PMTA meets regulatory requirements to be accepted and moves the application into the FDA's filing review phase.
John Patterson, President of IKE Tech, said: 'Receiving the Acceptance Review letter from the FDA faster than most applications is a major milestone for IKE Tech and a promising step forward for public health in the ENDS category. By leveraging Bluetooth, biometrics, and blockchain, we're unlocking a new era of vaping – one that gives regulators and manufacturers the power to lock out youth and ensure adult-only access. We're proud to be leading the way with a secure, scalable solution that could become the new baseline for responsible product access in the US and beyond.'
– ENDS –
Notes to Editors:
Human Factors Study Design and Key Results
Conducted with 102 participants (51% male, 49% female, aged 18–67 across race/ethnic demographics), the study simulated real-world use of the IKE system. Participants downloaded the app, verified their age, paired with a test device and interacted with BLE-based access controls including biometric activation.
Key performance highlights:
Devices could only be activated after successfully passing the age-gating process. Demographic data (age, race/ethnicity, gender) was accurately verified in all cases. The results confirm the IKE System's ability to reduce user error and prevent underage access.
About IKE Tech
IKE Tech LLC ('IKE Tech') is pioneering real-time age and identity verification at the point of use, helping to safeguard access to age-restricted products.
A leading innovator at the intersection of Internet of Things (IoT), identity verification (IDV), and tokenization technology, IKE Tech has developed an industry-first, scalable age-gating component that provides continuous, real-time verification for electronic nicotine delivery systems (ENDS) and other restricted consumer products.
IKE Tech's interoperable Bluetooth Low Energy (BLE) System-on-a-Chip, powered by a user-friendly mobile app available on iOS and Android, integrates seamlessly into ENDS devices, giving manufacturers and regulators a flexible, future-proofed solution to combat underage vaping and illicit markets. By setting the new standard for responsible, adult-only access, IKE Tech is helping eliminate youth vaping for good.
Media contact
[email protected]
View original content: https://www.prnewswire.com/news-releases/ike-techs-pmta-for-first-ever-standalone-age-gating-system-at-point-of-use-accepted-for-fda-review-just-one-month-after-submission-302472955.html
SOURCE IKE Tech LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
These Popular Eggs Are Being Recalled Over Salmonella Risk
If you've been living for your morning sunny-side eggs…well, brace yourself. The August Egg Company—the parent behind Sunnyside, Clover, Raley's, and a few other brands—is recalling a whopping 1.7 million dozen eggs due to a potential salmonella outbreak. Yep, it's serious.. The U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention have flagged the August Company's 'brown cage-free and brown certified organic egg' for possible contamination, meaning you might want to double-check that carton in your fridge before cracking it open. If you didn't know, Salmonella is that sneaky bacteria behind food poisoning and can cause anything from mild stomach upset to serious illness. These eggs were shipped to Walmart stores and other grocers in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. They have a best-by date from March 4 to June 19 and food codes P-6562 or CA5330. Not sure if your eggs are on the list? The FDA has a full rundown of all the recalled brands you can check out. And if the cartons in your fridge match any of the food codes or best-by-dates, toss them out immediately. While it's somewhat okay to eat an egg past its expiration date, this isn't the case. The FDA has already connected a current salmonella outbreak to the eggs. As of now, a total of 79 cases have been reported in seven states, while 21 people have been hospitalized. We get it: eggs are pricey, and tossing them feels like a waste. But don't risk it. Plus, most places will give you a full refund. And if your eggs touched any surfaces, wipe those down like your life depends on it. If after eating you feel dizzy, nauseous, or get a fever—don't play it cool. Call your doctor. This is serious business. Trust me, as a four-time survivor of food poisoning, you don't want to take any chances. You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
Yahoo
3 hours ago
- Yahoo
Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval
Sarepta Therapeutics saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year. This significant increase can be partially attributed to several key announcements, including the FDA's platform technology designation for their rAAVrh74 viral vector, pivotal updates from ongoing studies related to their ELEVIDYS treatment for Duchenne Muscular Dystrophy, and new approval in Japan. These developments highlight the company's continued progress and innovation in gene therapy, reinforcing investor confidence amidst market growth. We've identified 2 weaknesses for Sarepta Therapeutics (1 is a bit concerning) that you should be aware of. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Recent developments for Sarepta Therapeutics have sparked a positive response in short-term share price, primarily driven by advancements in their gene therapy programs. These innovations, particularly the FDA's designation and updates on the ELEVIDYS program, are poised to bolster investor confidence. However, despite this optimism, it's essential to acknowledge that Sarepta's shares have experienced a 37.80% decline over the past three years, highlighting challenges the company has faced. Relative to the biotechnology industry, Sarepta has underperformed in the past year compared to the US Biotechs market, which returned -9.3%. The recent announcements could potentially impact Sarepta's revenue and earnings forecasts considerably. Analysts project a significant annual revenue increase over the next three years, with expectations that profit margins will improve. Crucially, these updates could address operational delays and safety concerns surrounding ELEVIDYS, enhancing the therapy's credibility and market uptake. In terms of valuation, Sarepta's recent share price movements are in the context of an analyst price target of US$89.96, indicating further room for growth if the company's strategic objectives translate into financial success. These factors collectively shape a complex but promising outlook for Sarepta as it navigates both opportunities and challenges in its field. The valuation report we've compiled suggests that Sarepta Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SRPT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval
Sarepta Therapeutics saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year. This significant increase can be partially attributed to several key announcements, including the FDA's platform technology designation for their rAAVrh74 viral vector, pivotal updates from ongoing studies related to their ELEVIDYS treatment for Duchenne Muscular Dystrophy, and new approval in Japan. These developments highlight the company's continued progress and innovation in gene therapy, reinforcing investor confidence amidst market growth. We've identified 2 weaknesses for Sarepta Therapeutics (1 is a bit concerning) that you should be aware of. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Recent developments for Sarepta Therapeutics have sparked a positive response in short-term share price, primarily driven by advancements in their gene therapy programs. These innovations, particularly the FDA's designation and updates on the ELEVIDYS program, are poised to bolster investor confidence. However, despite this optimism, it's essential to acknowledge that Sarepta's shares have experienced a 37.80% decline over the past three years, highlighting challenges the company has faced. Relative to the biotechnology industry, Sarepta has underperformed in the past year compared to the US Biotechs market, which returned -9.3%. The recent announcements could potentially impact Sarepta's revenue and earnings forecasts considerably. Analysts project a significant annual revenue increase over the next three years, with expectations that profit margins will improve. Crucially, these updates could address operational delays and safety concerns surrounding ELEVIDYS, enhancing the therapy's credibility and market uptake. In terms of valuation, Sarepta's recent share price movements are in the context of an analyst price target of US$89.96, indicating further room for growth if the company's strategic objectives translate into financial success. These factors collectively shape a complex but promising outlook for Sarepta as it navigates both opportunities and challenges in its field. The valuation report we've compiled suggests that Sarepta Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SRPT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
